1. Scrip
  2. >>Business

Tezepelumab Deemed Breakthrough But Can Phase III Reproduce Data?

 
• By Sten Stovall

Biologic's breakthrough designation is based on Phase IIb PATHWAY data that showed tezepelumab significantly reduced asthma exacerbations compared to placebo in severe asthma.

Lungs
tezepelumab targets 'master switch' thought to control inflammatory pathways in patients with severe asthma • Source: Shutterstock

The FDA has granted AstraZeneca PLC's first-in-class tezepelumab breakthrough designation in patients with severe asthma, potentially accelerating its development and review. To successfully do that, though, the drug will need to reproduce the impressive clinical data supporting the decision in Phase III studies.

The breakthrough designation is based on Phase IIb PATHWAY data which showed tezepelumab significantly reduced asthma exacerbations compared with placebo...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By Andy Smith

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 
• By Andrew McConaghie

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.